Compare APRE & BLIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APRE | BLIN |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.1M |
| IPO Year | 2019 | 2018 |
| Metric | APRE | BLIN |
|---|---|---|
| Price | $0.80 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.10 | ★ $4.62 |
| AVG Volume (30 Days) | ★ 478.0K | 55.7K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,568,000.00 |
| Revenue This Year | N/A | $22.67 |
| Revenue Next Year | N/A | $21.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.69 |
| 52 Week High | $1.69 | $1.59 |
| Indicator | APRE | BLIN |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 39.09 |
| Support Level | $0.74 | $0.95 |
| Resistance Level | $0.81 | $1.08 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.80 | 21.00 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.